

**Supplementary Table 7.** Clinical and imaging findings associated with the progression-free survival: subgroup with FOLFOX/FOLFIRI only

	Univariable analysis			Multivariable analysis		
	Hazard ratio	95% CI	P-value	Hazard ratio	95% CI	P-value
Age (year)	1.042	0.975–1.114	0.227	–	–	–
Male sex	1.113	0.239–5.183	0.892	–	–	–
Serum CEA level (ng/mL)	1.001	0.999–1.002	0.589	–	–	–
Change in SWV value (%)	1.049	1.015–1.083	0.004*	1.057	1.004–1.113	0.036*
Non-responder (SD or PD)	15.97	1.921–132.7	0.010*	5.055	0.463–55.20	0.184
KRAS mutation	0.199	0.025–1.607	0.130	–	–	–
No. of CRLMs ≥5	9.506	1.680–53.80	0.011*	13.98	1.778–109.9	0.012*
Primary rectal cancer	1.545	0.447–5.339	0.492	–	–	–
Resection of primary cancer	N/A			–	–	–
Metachronous CRLM	0.377	0.047–3.010	0.357	–	–	–
Presence of lymph node metastasis of primary cancer	1.703	0.215–13.51	0.615	–	–	–

FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan; CI, confidence interval; CEA, carcinoembryonic antigen; SWV, shear-wave velocity; SD, stable disease; PD, progressive disease; KRAS, Kirsten rat sarcoma virus; CRLM, colorectal liver metastasis; N/A, not available.

\*P<0.05.

**Supplementary Table 8.** Clinical and imaging findings associated with the progression-free survival: subgroup with FOLFOX/FOLFIRI+bevacizumab

	Univariable analysis			Multivariable analysis		
	Hazard ratio	95% CI	P-value	Hazard ratio	95% CI	P-value
Age (year)	1.021	0.974–1.070	0.386	–	–	–
Male sex	2.094	0.787–5.566	0.139	–	–	–
Serum CEA level (ng/mL)	1.000	1.000–1.000	0.553	–	–	–
Change in SWV value (%)	1.009	0.987–1.031	0.412	–	–	–
Non-responder (SD or PD)	2.640	1.045–6.671	0.040*	–	–	–
KRAS mutation	0.343	0.078–1.500	0.155	–	–	–
No. of CRLMs ≥5	1.450	0.331–6.343	0.622	–	–	–
Primary rectal cancer	0.444	0.147–1.339	0.150	–	–	–
Resection of primary cancer	0.554	0.211–1.457	0.231	–	–	–
Metachronous CRLM	0.375	0.047–2.994	0.354	–	–	–
Presence of lymph node metastasis of primary cancer	0.789	0.226–2.755	0.710	–	–	–

FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan; CI, confidence interval; CEA, carcinoembryonic antigen; SWV, shear-wave velocity; SD, stable disease; PD, progressive disease; KRAS, Kirsten rat sarcoma virus; CRLM, colorectal liver metastasis.

\*P<0.05.